Clare Scott AM is a Medical Oncologist at the Peter MacCallum Cancer Centre and the Royal Melbourne and Royal Women’s Hospitals and is Joint Head, Clinical Discovery and Translation and Laboratory Head at the Walter and Eliza Hall Institute of Medical Research and Professor of Gynaecological Cancer at University of Melbourne. She has over 20 years’ experience in treating breast and ovarian cancer and in clinical cancer genetics in Familial Cancer Clinics. Clare has been Principal Investigator for more than ten ovarian cancer clinical trials of targeted therapy leading to high impact publications and is immediate past Chair of the ANZGOG OASIS Initiative Steering Committee. In the lab, Clare has developed new ovarian cancer pre-clinical models and is using genomics to study targeted drug combinations to combat drug resistance. Clare has established a rare cancer research program to improve access to targeted treatments for patients diagnosed with a rare cancer. Clare was awarded the Sir Edward Dunlop Cancer Research Fellowship from Cancer Council Victoria (2012) and a Clinical Research Fellowship from the Victorian Cancer Agency (2018).

Alison Brand AM is a gynaecological oncology surgeon, Director of Gynaecological Oncology at Westmead Hospital, Sydney, NSW and Clinical Professor at the University of Sydney. Alison has been involved in ANZGOG since it was established in 2000 and has since held key positions within the group. She was ANZGOG Chair from 2012 to 2018. Alison has chaired or been a member of several working parties for the development of national gynaecological cancer guidelines and has been PI on several international and national trials. She is current Chair of the Gynaecological Cancer Intergroup, an umbrella organisation of 33 international trials groups. In 2021, she was made Member, Order of Australia, for significant service to medicine, gynaecology, and medical organisations. She is passionate about participation in clinical trials as a way to improve the lives of women with gynaecological cancers, now and in the future.

Alison is a member of ANZGOG’s Research Advisory Committee and Research Management Group, TR-ANZGOG, OASIS Steering Committee and the Uterine Tumour Working Group. She is also the Deputy Chair of the EDEN Steering Committee and involved in the PRAiSED EDEN Focus Group.

Alison Davis is a Senior Staff Specialist in Medical Oncology at The Canberra Hospital and Clinical Associate Professor at the Australian National University. She has extensive clinical experience with sub-speciality expertise in gynaecological and breast malignancies. Her main research focus is Quality of Life (QOL) and End of Life (EOL) care in women with gynaecological malignancies. Alison is the immediate past Chair of the ANZGOG Research Advisory Committee, from 2017 to February 2023, is a member of the Research Management Group,  TR- ANZGOG Steering Committees and the Ovarian Tumour Working Group and is also a director of the ANZGOG Board. She is currently also a member of the ACT HREC clinical trial subcommittee, ACT SE NSW Breast Cancer Treatment Group and Australian Breast Cancer Tissue Bank.

Michelle Wilson is a medical oncologist who subspecialises in gynaecological cancers and early-phase clinical trials. She is the clinical director for Cancer and Blood Research at Auckland City Hospital. Dr Wilson is a very active researcher and is also one of 4 Principal Investigators with the early phase Auckland Cancer Trials Centre. Dr Wilson’s research focus is geared towards early phase translational studies and clinical trial endpoints, in particular their utility and evolution in the era of precision oncology. She was awarded a medical doctorate on this topic in 2018 through the University of Auckland. Dr Wilson is a member of the Ovarian Tumour Working Group, the ANZGOG Research Advisory Committee, the OASIS Steering Committee. She is New Zealand Director for ANZGOG.

Paul Cohen is a Consultant at the Western Australian Gynaecological Cancer Service, King Edward Memorial Hospital and Clinical Professor at the University of Western Australia. Paul’s research interests include prediction of histological tumour regression in women with high-grade serous ovarian cancer following neoadjuvant chemotherapy, the supportive care of women affected by gynaecological cancers, and gynaecological cancer epidemiology.

Paul is the current chair of the ANZGOG Research Advisory Committee, Chair of the International Gynecological Cancer Society (IGCS) Education Committee, and a Board Director of the IGCS. Paul is a member of the eviQ Cancer Genetics Reference Committee, and a member of the Editorial Boards of the International Journal of Gynecological Cancer and Scientific Reports.

Associate Professor Pearly Khaw is currently the lead Radiation Oncologist in Gynae/Oncology at the Peter MacCallum Cancer Centre. She has over 20 years of experience in radiation oncology, 18 of those years specialising in the management of gynaecological cancer patients. She is a clinician-researcher and is actively involved in ANZGOG, and is a member of the EDEN Steering Committee and the Uterine Tumour Type Working Group. She is the current IGCS (International Gynecology Cancer Society) Radiation Oncology Education Chair, a member of the Editorial Board of the IJGC (International Journal of Gynaecological Cancer) and Associate Editor (Gynae-Oncology) for JMIRO (Journal of Medical Imaging and Radiation Oncology). She was previously the Deputy Chair of the Treatment Sub-Advisory Group for the National Cervical Cancer Elimination Strategy (Australia), and is currently involved in the updating of the Optimal Care Pathway for Cervical Cancer.

Tarek Meniawy is a medical oncologist who subspecialises in melanoma, gynaecological cancers as well as early-phase clinical trials. He is an Adjunct Associate Professor at Edith Cowan University and a Clinical Associate Professor at the University of Western Australia, where he was awarded a PhD degree in 2016. He is also a Principal Investigators at Linear Clinical Research, the only dedicated Phase I clinical trial unit in Western Australia, and one of a handful of such dedicated units in Australia.

Dr Meniawy is the immediate past Chair of the OASIS Steering Committee and a member of the ANZGOG Research Advisory Committee and the Ovarian Tumour Working Group. He is also a member of the statewide Western Australia Gynaecologic Cancer Service (WAGCS), as well as the WA Kirkbride Melanoma Advisory Service

ANZGOG – Director, Deputy Chair – Research Advisory Committee, Lead of EDEN’s Adjuvant and Metastatic Therapies Focus Group, EDEN Steering Committee

Associate Professor Yoland Antill is a Medical Oncologist and Cancer Genetics specialist based at Cabrini Health, Frankston Hospital and Royal Melbourne Hospital in Victoria. She holds an adjunct clinical position in the Faculty of Medicine, Dentistry and Health Sciences at Monash University. While trained at the University of Newcastle and Royal North Shore in Sydney, NSW, she now calls Melbourne home.

A/Prof Antill’s working and research interests are in the management of Gynaecological and Breast cancers together with Hereditary Cancer Syndromes. She is the current Deputy Chair of ANZGOG Research Advisory Committee, Lead of EDEN’s Adjuvant and Metastatic Therapies Focus Group, a member of ANZGOG’s EDEN Steering Committee and ex-officio of the ANZGOG Uterine Tumour Working Group.  She also is a member of Australia’s Breast Cancer Trials Group, the Medical Oncology Group of Australia and the American Society of Clinical Oncology.

A/Prof Antill has published widely in the areas of hereditary cancer risk breast and gynaecological cancers and is regularly invited to speak at national and international meetings.  She is the lead investigator for a number of local and international research studies and is involved in the development and conduct of clinical and supportive care trials. A/Prof Antill has more than 20 years’ experience in both medical oncology and in the diagnosis and management of hereditary cancer syndromes.

Fiona is a chartered accountant, CA, and joined the ANZGOG Board as Finance Director in May 2021. Fiona started her career with professional services firm Ernst & Young where she spent 10 years in the Audit Division in Sydney and London. Moving to senior finance
roles in ASX listed Corporates for 17 years Fiona was able to navigate complex business structures and acquisitions to simplify financial reporting and provide insightful information to stakeholders. More recently Fiona has held CFO roles at not-for-profit organisations.

Fiona brings strong corporate governance and risk management experience. Her ability to explain financial concepts in operational language and empower people to understand and use financial information drives better decision making. Known for her trust and integrity Fiona’s guidance helps boards and executives manage financial risk. Fiona is an Audit Committee member for the Inspector-General of Taxation and Taxation Ombudsman (IGTO) and is the Chair of the ANZGOG Audit Risk and Compliance Committee.

Donna Long is currently the Manager of the Regional Trials Network – Victoria. The Network membership includes 8 Clinical Trials Units in Regional Victoria and managers Government funded projects like the Regional Victorian Trials alliance: Linkages, Innovation, Special populations, Equity (ReViTALISE) project. Donna has had a long history in the oncology sector starting in nursing while training at the Royal Prince Alfred Hospital. Donna has over 35 years’ experience in Oncology including 12 years in the Gynaecological Oncology surgical unit at The Royal Hospital for Women in Sydney and 13 years’ experience as a Research Nurse/Study Coordinator at Border Medical Oncology Research Unit in Albury. Donna’s experience includes Palliative Care at Sacred Heart Hospice in Sydney, Breast Cancer Peer Support Coordinator at the Cancer Council NSW, and experience as a Service Improvement Facilitator for the Hume Regional Integrated Cancer Service. Donna has been a member of ANZGOG and the study coordinators committee since 2006 and is a past Chair that Committee from 2020 – 2023.